Key Starting News Today : Breaking News, Live Updates & Top Stories | Vimarsana

India's total imports from China increased by nearly 29 per cent in the past five years

Budget 2021 could be the vaccine for the pharmaceutical industry Given the government’s ambition to make India a $5 trillion economy in the next five years, pharmaceutical and life science could be the ‘target sector’ in Budget 2021 Hitesh Sharma Representative Image The pharmaceutical and life science sector has played a pivotal role during this ongoing pandemic which has shook the world economy, India being no different. Being an essential sector, it actually rose to the occasion — first in identifying and supplying medicines to control t...

With inelastic demand for drugs and resumption of production to the near pre-Covid levels by Q3 FY2021, revenue growth for IPM (Indian Pharmaceutical Market) is expected to be 7-9 per cent in FY2021 despite muted growth in Q1 FY2021, ratings agency ICRA said in a report. The revenue growth in FY2022 is expected to be slightly better at 8-11 per cent, though lower incidences of acute diseases, lesser OPDs and elective surgeries may continue to have some bearing on growth and will depend upon the course of the pandemic, the report added. The API/KSM (Key Starting mAterials) supplies from Chi...

Pharma sector revenue, margins likely to remain healthy in FY2022: ICRA ​ By IANS | Published on ​ Wed, Dec 23 2020 15:27 IST | ​ 0 Views ICRA. (Photo: ICRA). Image Source: IANS News New Delhi, Dec 23 : With inelastic demand for drugs and resumption of production to the near pre-Covid levels by Q3 FY2021, revenue growth for IPM (Indian Pharmaceutical Market) is expected to be 7-9 per cent in FY2021 despite muted growth in Q1 FY2021, ratings agency ICRA said in a report. The revenue growth in FY2022 is expected to be slightly better at 8-11 per cent, though lower incidences of acute...